IP Library Granted Patent US 8,524,193
Granted Patent B2
US 8,524,193 · App. 10/503,690 · Granted Sep 3, 2013

Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts

Inventors: Igal Madar (Baltimore, MD); Hayden T. Ravert (Bel Air, MD); Robert Francis Dannals (Sparks, MD); Ursula A. Scheffel (Baltimore, MD); James J. Frost (Baltimore, MD)
Assignee: The Johns Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,193
App. No.
10/503,690
Granted
Sep 3, 2013
Kind
B2
Abstract

The invention provides lipophilic salts, particularly, lipophilic salts comprising a pharmaceutically acceptable anion and at least one phosphonium or ammonium cation. In certain embodiments, the cation is labeled with one or more radioisotopes. The lipophilic salts of the invention exhibit an affinity for dysfunctional mitochondria, and are useful for the imaging of cardiovascular diseases and disorders. The invention also provides pharmaceutical compositions and methods of using the lipophilic salts.

Claims (16)

1. A method of imaging cardiac infarction, cardiac perfusion, heart failure, cardiomyopathy or ischemia comprising:

providing a radiolabeled salt comprising at least one pharmaceutically acceptable anion and 18 F-4-fluorobenzyl-triphenylphosphonium ion;

contacting cells or tissues in a subject with the radiolabeled salt; and

making a radiographic image.

2. The method of claim 1 , wherein the image correlates with mitochondrial membrane potential (ΔΨm).

3. The method of claim 2 , wherein the image correlates with suppressed or enhanced apoptosis.

4. The method of claim 1 , wherein the image correlates with imaging mitochondrial dysfunction.

5. The method of claim 1 , wherein the radiolabeled salt exhibits a target to non-target ratio of at least about 5:1.

6. The method of claim 1 , wherein the radiolabeled salt is stable in vivo.

7. The method of claim 1 , wherein the radiolabeled salt substantially localizes to a site or sites having dysfunctional mitochondria within about 120 minutes after administration.

8. The method of claim 1 , wherein the radiolabeled salt substantially localizes to a site or sites dysfunctional mitochondria within about 60 minutes after administration.

9. The method of claim 1 , wherein the radiolabeled salt substantially localizes to a site or sites dysfunctional mitochondria within about 30 minutes after administration.

10. The method of claim 1 , wherein the radiolabeled salt is detected by a gamma camera, positron emission tomography (PET) or single photon emission tomography (SPECT).

11. The method of claim 1 , wherein the subject is a human, rat, mouse, cat, dog, horse, sheep, cow, monkey, avian, or amphibian.

12. The method of claim 1 , wherein the cell is a myocyte.

13. The method of any one of claims 7 - 9 , wherein the site or sites are in the myocardium.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 31, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044339/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2005
From: MADAR, IGAL; RAVERT, HAYDEN T.; DANNALS, ROBERT F.; SCHEFFEL, URSULA A.; FROST, J. JAMES
To: JOHNS HOPKINS UNIVERSITY
Reel/Frame 016032/0123 →
Continuity (2)
Provisional Application 60354563 · Feb 6, 2002
Related Publication 20050182027A1 · Aug 18, 2005